Results 131 to 140 of about 226,833 (317)

ECG In Evaluation for Pulmonary Thromboembolism- Occam’s Razor or Hickam’s Dictum? [PDF]

Journal of Clinical and Diagnostic Research, 2016
Ram V. Nampoothi, Arjun Lakshman, Ashish Bhalla, Subhash Varma   +3 more
doaj   +1 more source

Maternal tachycardia in pregnancy: a masked presentation of hyperthyroidism?

Акушерство, гинекология и репродукция
Introduction. Hyperthyroidism occurs in 35–50 per 100,000 women aged 20–29 years annually. Pregnancy outcomes in hyperthyroid mothers depend heavily on metabolic control.
A. Everdien, M. A. Aziz, A. Kurniadi, A. Sh. Nisa, D. H. Subhan   +4 more
doaj   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Dynamic interpretation of tachycardia in trauma: A case report with a retrospective exploration of the potential role of artificial intelligence in early identification of complications

Journal of Current Research in Scientific Medicine
Tachycardia is a frequent physiological abnormality in trauma patients and is often reflexly attributed to hemorrhagic shock. Advances in trauma care have improved survival but have increased the incidence of complications related to resuscitation ...
Angeline Neetha Radjou, Achu Jacob Philip   +1 more
doaj   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Tachycardia [PDF]

BMJ, 1953
openaire   +2 more sources

Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak‐Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś   +12 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Idiopathic ventricular tachycardia. [PDF]

, 1999
Most ventricular tachycardias encountered in clinical practice occur in patients who have structural heart disease. Idiopathic ventricular tachycardia refers to those arrhythmias that occur in patients without structural heart disease, metabolic ...
Buxton, A E, Altemose, G T
core